CL2020002574A1 - Análogos novedosos de glp-1 - Google Patents

Análogos novedosos de glp-1

Info

Publication number
CL2020002574A1
CL2020002574A1 CL2020002574A CL2020002574A CL2020002574A1 CL 2020002574 A1 CL2020002574 A1 CL 2020002574A1 CL 2020002574 A CL2020002574 A CL 2020002574A CL 2020002574 A CL2020002574 A CL 2020002574A CL 2020002574 A1 CL2020002574 A1 CL 2020002574A1
Authority
CL
Chile
Prior art keywords
analogs
glp
present disclosure
new
action
Prior art date
Application number
CL2020002574A
Other languages
English (en)
Inventor
Rajamannar Thennati
Nishith Chaturvedi
Vinod Sampatrao Burade
Pradeep Dinesh Shahi
Muthukumaran Natarajan
Ravishankara Madavati Nagaraja
Rishit Mansukhlal Zalawadia
Kunal Pandya
Brijeshkumar Patel
Dhiren Rameshchandra Joshi
Krunal Harishbhai Soni
Abhishek Tiwari
Vipulkumar Shankarbhai Patel
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of CL2020002574A1 publication Critical patent/CL2020002574A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transmission And Conversion Of Sensor Element Output (AREA)

Abstract

La presente revelación pertenece a los nuevos análogos del Glucagón como el Péptido-1 (GLP-1) (7-37) que tienen una secuencia de aminoácidos con Leu o Ile en el C-terminal. Los nuevos análogos son potentes agonistas del GLP-1 con un efecto adverso reducido y una mejor duración de la acción. La presente divulgación se refiere además a los derivados acilados de los nuevos análogos que han mejorado aún más la potencia y la duración de la acción y son adecuados para la administración oral. Los análogos de la presente divulgación pueden ser útiles en el tratamiento de la diabetes y la obesidad.
CL2020002574A 2018-04-05 2020-10-05 Análogos novedosos de glp-1 CL2020002574A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201821013109 2018-04-05
IN201821040468 2018-10-26
IN201821040474 2018-10-26

Publications (1)

Publication Number Publication Date
CL2020002574A1 true CL2020002574A1 (es) 2021-06-04

Family

ID=66589592

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002574A CL2020002574A1 (es) 2018-04-05 2020-10-05 Análogos novedosos de glp-1

Country Status (28)

Country Link
US (5) US11447535B2 (es)
EP (3) EP4364751A2 (es)
JP (2) JP7250814B2 (es)
KR (1) KR20200141469A (es)
CN (2) CN112236444A (es)
AU (2) AU2019247936C1 (es)
BR (1) BR112020020419A2 (es)
CA (1) CA3095988A1 (es)
CL (1) CL2020002574A1 (es)
CO (1) CO2020012425A2 (es)
DK (1) DK3774862T3 (es)
EC (1) ECSP20070185A (es)
ES (1) ES2925678T3 (es)
HR (1) HRP20221054T1 (es)
HU (1) HUE060135T2 (es)
IL (1) IL277483A (es)
JO (1) JOP20200251A1 (es)
LT (1) LT3774862T (es)
MX (1) MX2020010505A (es)
PE (1) PE20211417A1 (es)
PH (1) PH12020551591A1 (es)
PL (1) PL3774862T3 (es)
PT (1) PT3774862T (es)
RS (1) RS63523B1 (es)
SG (1) SG11202009467YA (es)
SI (1) SI3774862T1 (es)
WO (1) WO2019193576A1 (es)
ZA (1) ZA202306729B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11622996B2 (en) 2018-05-07 2023-04-11 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202009467YA (en) * 2018-04-05 2020-10-29 Sun Pharmaceutical Ind Ltd Novel glp-1 analogues
TW202216746A (zh) * 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
BR112023003668A2 (pt) * 2020-10-17 2023-04-25 Sun Pharmaceutical Ind Ltd Agonistas duplos de glp-1/gip
CN114685646B (zh) * 2020-12-31 2023-04-07 厦门赛诺邦格生物科技股份有限公司 一种多肽侧链类似物的制备方法及其应用
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
CN115785249B (zh) * 2022-10-13 2023-07-21 江苏师范大学 一类glp-1类似物及其应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
EP1060191B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
WO1999043705A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR100511855B1 (ko) 1998-12-07 2005-09-02 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. Ｇｌｐ-1의 유사체
DK1294757T3 (da) 2000-06-16 2007-03-19 Lilly Co Eli Glucagonlignende peptid 1-analoger
DK1724284T3 (da) 2000-12-07 2009-11-02 Lilly Co Eli GLP-1 fusionsproteiner
JP4282485B2 (ja) 2002-01-08 2009-06-24 イーライ リリー アンド カンパニー 伸長グルカゴン様ペプチド−１アナログ
KR20050049525A (ko) 2002-10-11 2005-05-25 가부시키가이샤산와카가쿠켄큐쇼 Ｇｌｐ-1 유도체 및 그의 경점막 흡수형 제제
EP1626981A4 (en) 2003-03-04 2006-11-22 Biorexis Pharmaceutical Corp PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE
CN102174102A (zh) 2003-05-15 2011-09-07 塔夫茨大学信托人 肽和多肽药物的稳定类似物
EP2932981B1 (en) 2003-09-19 2021-06-16 Novo Nordisk A/S Albumin-binding derivatives of GLP-1
CA2551039C (en) 2003-12-16 2013-01-29 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Analogues of glp-1
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
RU2007134155A (ru) 2005-03-18 2009-04-27 Ново Нордиск А/С (DK) Glp-1 соединения с увеличенным временем полужизни
EP1883419A4 (en) 2005-05-06 2010-08-04 Bayer Pharmaceuticals Corp GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES
KR20080052649A (ko) 2005-09-08 2008-06-11 트러스티즈 오브 터프츠 칼리지 안정화된 ｇｌｐ―1 유사체
ES2336575T3 (es) 2005-09-22 2010-04-14 Biocompatibles Uk Limited Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa.
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2214691B1 (en) 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
MX2012006634A (es) 2009-12-16 2012-06-21 Novo Nordisk As Derivados de peptidos tipo glucagon 1 de doble acilato.
SG185066A1 (en) 2010-04-27 2012-12-28 Zhejiang Beta Pharma Inc Glucagon-like peptide-1 analogue and use thereof
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
CN105601729A (zh) 2010-11-09 2016-05-25 诺沃—诺迪斯克有限公司 双-酰化的glp-1衍生物
JP6022538B2 (ja) 2011-04-12 2016-11-09 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
CN104039822A (zh) 2011-09-06 2014-09-10 诺沃—诺迪斯克有限公司 Glp-1衍生物
EP2578599A1 (en) 2011-10-07 2013-04-10 LanthioPep B.V. Cyclic analogs of GLP-1 and GLP-1 related peptides
WO2013167454A1 (en) 2012-05-08 2013-11-14 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2013167455A1 (en) 2012-05-08 2013-11-14 Novo Nordisk A/S Double-acylated glp-1 derivatives
JP2015525226A (ja) 2012-06-14 2015-09-03 サノフイ エキセンディン−４ペプチドアナログ
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
PL2934567T3 (pl) 2012-12-21 2018-10-31 Sanofi Pochodne eksendyny-4 jako podwójny agonista GLP1/GIP lub potrójny agonista GLP1/GIP/glukagon
KR20160021183A (ko) 2013-06-20 2016-02-24 노보 노르디스크 에이/에스 Glp-1 유도체 및 그것의 용도
WO2014209886A1 (en) 2013-06-23 2014-12-31 Wisconsin Alumni Research Foundation Alpha/beta-polypeptide analogs of glucagon-like peptid-1
CN105377884B (zh) 2013-07-04 2021-07-20 诺和诺德股份有限公司 Glp-1样肽的衍生物和其用途
JP6599863B2 (ja) 2013-08-15 2019-10-30 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
PT3057984T (pt) * 2013-10-17 2018-10-24 Boehringer Ingelheim Int Análogos de glucagon acilados
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
CN105849123A (zh) 2013-12-13 2016-08-10 免疫医疗有限公司 蛋白酶抗性肽
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2016083499A1 (en) 2014-11-27 2016-06-02 Novo Nordisk A/S Glp-1 derivatives and uses thereof
CN107108714B (zh) 2014-12-17 2022-02-08 诺和诺德股份有限公司 Glp-1衍生物及其用途
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
WO2017035432A1 (en) 2015-08-26 2017-03-02 Robert Doyle Coagonists of glucagon-like peptide 1 receptor and neuropeptide y2 receptor
CN108699126B (zh) 2016-03-03 2022-12-06 诺和诺德股份有限公司 Glp-1衍生物及其用途
WO2017211922A2 (en) 2016-06-09 2017-12-14 Medimmune Limited Protease-resistant mono-lipidated peptides
EP3534962B1 (en) 2016-11-07 2020-08-19 Novo Nordisk A/S Dchbs-active esters of peg compounds and their use
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
WO2018178796A1 (en) * 2017-03-27 2018-10-04 Sun Pharmaceutical Industries Limited Method for making kex1 protease sensitive polypeptides using yeast strain
CN111819191A (zh) 2018-03-09 2020-10-23 恩细贝普有限公司 利拉鲁肽、索马鲁肽和glp-1的化学酶促合成
SG11202009467YA (en) * 2018-04-05 2020-10-29 Sun Pharmaceutical Ind Ltd Novel glp-1 analogues

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11622996B2 (en) 2018-05-07 2023-04-11 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid

Also Published As

Publication number Publication date
AU2019247936C1 (en) 2023-06-15
US20220402991A1 (en) 2022-12-22
IL277483A (en) 2020-11-30
HRP20221054T1 (hr) 2022-11-11
PE20211417A1 (es) 2021-08-02
JP2023078367A (ja) 2023-06-06
AU2019247936B2 (en) 2023-03-02
US11485766B2 (en) 2022-11-01
HUE060135T2 (hu) 2023-02-28
EP3774862A1 (en) 2021-02-17
US11242373B2 (en) 2022-02-08
JP7250814B2 (ja) 2023-04-03
US20210206823A1 (en) 2021-07-08
EP4122954A1 (en) 2023-01-25
EP3774862B1 (en) 2022-06-08
ES2925678T3 (es) 2022-10-19
SG11202009467YA (en) 2020-10-29
US11447535B2 (en) 2022-09-20
WO2019193576A1 (en) 2019-10-10
US20190309040A1 (en) 2019-10-10
CO2020012425A2 (es) 2020-12-21
PH12020551591A1 (en) 2021-08-16
US11873328B2 (en) 2024-01-16
US20200362007A1 (en) 2020-11-19
CA3095988A1 (en) 2019-10-10
MX2020010505A (es) 2021-01-15
JOP20200251A1 (ar) 2020-10-04
BR112020020419A2 (pt) 2021-01-19
ECSP20070185A (es) 2021-01-29
EP4122954B1 (en) 2024-04-03
EP4364751A2 (en) 2024-05-08
SI3774862T1 (sl) 2022-10-28
US20220402992A1 (en) 2022-12-22
US11866477B2 (en) 2024-01-09
JP2021520346A (ja) 2021-08-19
DK3774862T3 (da) 2022-09-05
AU2019247936A1 (en) 2020-10-15
RS63523B1 (sr) 2022-09-30
KR20200141469A (ko) 2020-12-18
LT3774862T (lt) 2022-09-12
PL3774862T3 (pl) 2022-10-03
CN112236444A (zh) 2021-01-15
CN117964735A (zh) 2024-05-03
ZA202306729B (en) 2024-03-27
AU2023203430A1 (en) 2023-06-29
PT3774862T (pt) 2022-09-05

Similar Documents

Publication Publication Date Title
CL2020002574A1 (es) Análogos novedosos de glp-1
PE20220590A1 (es) Agonistas del receptor del peptido-1 similar al glucagon
CL2017001760A1 (es) Compuestos co-agonistas de gip y glp-1
AR067555A1 (es) Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
CO6280539A2 (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabolicos y obesidad
ECSP19046893A (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip
PE20180158A1 (es) Coagonistas de los receptores de glucagon y de glp-1
AR099975A1 (es) Derivados de exendina-4 como agonistas peptídicos duales del receptor de glp-1 / glucagón
CL2020002796A1 (es) Derivados de gip y usos de estos
AR081200A1 (es) Formulaciones de insulina de accion prolongada
PE20170087A1 (es) Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon
CL2019001552A1 (es) Agonistas duales acilados de glp-1/glp-2.
PE20240215A1 (es) Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
AR094181A1 (es) Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon
PE20151770A1 (es) Compuesto peptidico
CY1116917T1 (el) Αναλογα οξυντομοντουλινης
AR109274A2 (es) Composición que comprende uno o más fragmentos de péptido intestinal vasoactivo (vip) y su uso para la fabricación de un medicamento
PE20200606A1 (es) Composiciones solidas para administracion oral
AR093903A1 (es) Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad
GT201700224A (es) Proteína de unión a rgma y su uso
AR105284A1 (es) Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
PE20171380A1 (es) Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
EA201890163A1 (ru) Композиция фолликулостимулирующего гормона млекопитающего с повышенной стабильностью
PE20221518A1 (es) Analogos de incretina y sus usos